JP2020523332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523332A5 JP2020523332A5 JP2019568064A JP2019568064A JP2020523332A5 JP 2020523332 A5 JP2020523332 A5 JP 2020523332A5 JP 2019568064 A JP2019568064 A JP 2019568064A JP 2019568064 A JP2019568064 A JP 2019568064A JP 2020523332 A5 JP2020523332 A5 JP 2020523332A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- substituents selected
- fluoroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridadinyl Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 9
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517203P | 2017-06-09 | 2017-06-09 | |
| US62/517,203 | 2017-06-09 | ||
| PCT/US2018/036624 WO2018227058A1 (en) | 2017-06-09 | 2018-06-08 | Piperidinone formyl peptide 2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523332A JP2020523332A (ja) | 2020-08-06 |
| JP2020523332A5 true JP2020523332A5 (enExample) | 2021-07-26 |
| JP7098663B2 JP7098663B2 (ja) | 2022-07-11 |
Family
ID=62779077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568064A Active JP7098663B2 (ja) | 2017-06-09 | 2018-06-08 | ピペリジノンホルミルペプチド２受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11008301B2 (enExample) |
| EP (1) | EP3634955B1 (enExample) |
| JP (1) | JP7098663B2 (enExample) |
| KR (1) | KR102615095B1 (enExample) |
| CN (1) | CN110997652B (enExample) |
| ES (1) | ES2869129T3 (enExample) |
| WO (1) | WO2018227058A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) * | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| JP7088965B2 (ja) | 2017-06-09 | 2022-06-21 | ブリストル－マイヤーズ スクイブ カンパニー | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678913B2 (en) | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| KR20140145203A (ko) * | 2012-04-16 | 2014-12-22 | 알러간, 인코포레이티드 | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 |
| RS57036B1 (sr) | 2013-11-28 | 2018-05-31 | Kyorin Pharmaceutical Co Ltd | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1) |
| CN107848962B (zh) | 2015-05-27 | 2021-04-09 | 杏林制药株式会社 | 脲衍生物或其药理学上可接受的盐 |
| ES2814126T3 (es) * | 2015-05-27 | 2021-03-26 | Kyorin Seiyaku Kk | Derivado de urea o sal farmacológicamente aceptable del mismo |
| MX2018005756A (es) * | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) * | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| US20200069644A1 (en) * | 2017-05-22 | 2020-03-05 | Bristol- Myers Squibb Company | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
| KR102623473B1 (ko) * | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| JP7088965B2 (ja) | 2017-06-09 | 2022-06-21 | ブリストル－マイヤーズ スクイブ カンパニー | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| US11180490B2 (en) * | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) * | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
-
2018
- 2018-06-08 WO PCT/US2018/036624 patent/WO2018227058A1/en not_active Ceased
- 2018-06-08 US US16/619,960 patent/US11008301B2/en active Active
- 2018-06-08 CN CN201880050616.6A patent/CN110997652B/zh active Active
- 2018-06-08 JP JP2019568064A patent/JP7098663B2/ja active Active
- 2018-06-08 EP EP18735092.1A patent/EP3634955B1/en active Active
- 2018-06-08 KR KR1020207000291A patent/KR102615095B1/ko active Active
- 2018-06-08 ES ES18735092T patent/ES2869129T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523332A5 (enExample) | ||
| JP2020523331A5 (enExample) | ||
| US10772893B2 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| JP2021516240A5 (enExample) | ||
| KR20140003436A (ko) | 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 아미노알코올 치환된 2,3-디하이드로이미다조[1,2-ｃ]퀴나졸린 유도체 | |
| US20160311833A1 (en) | Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | |
| US20190142812A1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP6001049B2 (ja) | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 | |
| CA3071760A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| PT2791136E (pt) | Triazolpiridinas substituídas e respectiva utilização como inibidores de ttk | |
| WO2018077944A2 (en) | 4,5-annulated 1,2,4-triazolones | |
| JP2015514806A5 (enExample) | ||
| CN103717604A (zh) | 取代的氨基咪唑并哒嗪 | |
| JP2019505541A5 (enExample) | ||
| JP2016506943A (ja) | Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類 | |
| EP3099682A1 (en) | Amino-substituted isothiazoles | |
| JP2017505793A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| CN117500507A (zh) | 作为新的sos1抑制剂的磷衍生物 | |
| RU2019144010A (ru) | Пиразолопиримидиновые ингибиторы pde9 | |
| JP2019535825A5 (enExample) | ||
| WO2017102091A1 (en) | Heteroarylbenzimidazole compounds | |
| JP2015513559A (ja) | 置換イミダゾピリダジン | |
| WO2015113927A1 (en) | Amino-substituted isothiazoles |